AGA Reading Room
High Cure Rates for HCV Patients Undergoing Liver Transplant with New DAAs
Indications that post-transplant treatment should start sooner rather than later
by
Contributing Writer, MedPage Today
For hepatitis C patients who receive liver transplants, a population that is challenging to treat with interferon-based therapy, treatment with new direct-acting antivirals (DAAs) leads to high cure rates.
The choice of which DAA to use depends on the hepatitis C virus (HCV) genotype and the severity of liver damage. Outcomes are better in people who have not yet developed severe damage in the new liver, suggesting that post-transplant treatment should be started sooner rather than later.
Continue reading....
No comments:
Post a Comment